Low tumour burden is associated with observation after surgery in patients with grade 2 astrocytoma and oligodendroglioma: results from the prospective multicentre LoG-Glio registry
Authors:
Open Access
- 15 October 2025
- journal article
- case study
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 176 (1) , 1-10
Abstract
Purpose: Recent evidence-based guidelines recommend adjuvant therapy following surgery for most patients with WHO grade 2 and 3 gliomas. However, deviations from these recommendations are frequently observed in clinical practice. This study aimed to evaluate patterns of postoperative management across Germany, using multicentre registry data from certified neuro-oncology centres. Methods: We analysed data from the ongoing multicentre registry study, which prospectively collects adult patients with IDH-mutant WHO grade 2 and 3 diffuse gliomas. Patients treated at 14 certified neuro-oncology centres were included. Multivariate logistic regression was used to identify factors associated with observation, chemotherapy, or radiotherapy. We assessed concordance between guideline recommendations and actual treatment during the first year after surgery. Results: A total of 217 patients with astrocytoma or oligodendroglioma were included, of whom 169 (78%) had WHO grade 2 tumours. Observation alone was selected in 90 (53%) patients with grade 2 tumours. Gross total resection was independently associated with observation (OR 0.10; 95% CI, 0.04–0.22; p < 0.001). In patients aged ≥ 40 years, adjuvant treatment decisions deviated from current guidelines (OR 3.15; 95% CI, 1.70–5.95; p = 0.001), although age itself was not an independent predictor of treatment choice in multivariate models. Conclusion: The presence of residual tumour after surgery was the principal determinant of postoperative management in patients with WHO grade 2 gliomas. Age ≥ 40 years did not independently influence clinical decision-making. These findings highlight a gap between guidelines and real-world practice and underscore the need for more flexible, individualised treatment frameworks.Keywords
Funding Information
- Universitätsklinikum Ulm
This publication has 35 references indexed in Scilit:
- European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomasThe Lancet Oncology, 2017
- Surgical resection versus watchful waiting in low-grade gliomasAnnals of Oncology, 2017
- Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup studyThe Lancet Oncology, 2016
- Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade GliomaNew England Journal of Medicine, 2016
- Effect of the Addition of Chemotherapy to Radiotherapy on Cognitive Function in Patients With Low-Grade Glioma: Secondary Analysis of RTOG 98-02Journal of Clinical Oncology, 2014
- Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 casesJournal of Neurosurgery, 2013
- Randomized Trial of Radiation Therapy Plus Procarbazine, Lomustine, and Vincristine Chemotherapy for Supratentorial Adult Low-Grade Glioma: Initial Results of RTOG 9802Journal of Clinical Oncology, 2012
- Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-upThe Lancet Neurology, 2009
- Effects of Radiotherapy on Cognitive Function in Patients With Low-Grade Glioma Measured by the Folstein Mini-Mental State ExaminationJournal of Clinical Oncology, 2003
- Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade GliomaJournal of Clinical Oncology, 2002